Convergence on the Constraints and Challenges in the Awareness, Prevention, Treatment and CONTROL OF TYPE 2 DIABETES and Diabetes-Related Conditions
Keywords:
cardiovascular diseases; dipeptidyl peptidase-4 inhibitors; insulin analogues; lignans, phytoestrogens, lifestyle changes
Abstract
The global epidemiology of type 2 diabetes over time regarding the biologic, cultural, demographic, therapeutic regimen and lifestyle changes are factors which have been described with particular focus on the aetiology, complications, natural history and risks pertaining to the disorder. Expansive data depict that type 2 diabetes incidence and prevalence increase rapidly to the detriment of pecuniary measures in health services and society. Recent decades have been encumbered with tumultuous and contentious polemics marked with conflicts in research findings and budget cuts in the awareness, prevention, treatment and control of the constraints and challenges regarding diabetes and related conditions, especially in LIMCs. Our health systems are faced with adverse policy expansiveness to unavoidable or threatened accelerating global needs in health and development as well as a realizable paradigm of performing more with less. Strategies in the prevention, treatment and control of type 2 diabetes and diabetes-related conditions aim to mitigate the risk of the development of diabetes and its complications.
Downloads
- Article PDF
- TEI XML Kaleidoscope (download in zip)* (Beta by AI)
- Lens* NISO JATS XML (Beta by AI)
- HTML Kaleidoscope* (Beta by AI)
- DBK XML Kaleidoscope (download in zip)* (Beta by AI)
- LaTeX pdf Kaleidoscope* (Beta by AI)
- EPUB Kaleidoscope* (Beta by AI)
- MD Kaleidoscope* (Beta by AI)
- FO Kaleidoscope* (Beta by AI)
- BIB Kaleidoscope* (Beta by AI)
- LaTeX Kaleidoscope* (Beta by AI)
How to Cite
References
L. Augustin, C. Kendall, D. Jenkins, W. Willett, Astrup H, Barclay A.W (2015) Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). 25(9), 795-815. https://doi.org/10.1016/j.numecd.2015.05.005
D. Aune, B. Ó Hartaigh, L. Vatten (2015) Resting heart rate and the risk of type 2 diabetes: A systematic review and dose-response meta-analysis of cohort studies. 25(6), 526-534. https://doi.org/10.1016/j.numecd.2015.02.008
M. Bashir, M. Pathan, S. Raza, J. Ahmad, A. Azad, O. Ishtiaq (2012) Role of oral hypoglycemic agents in the management of type 2 diabetes mellitus during Ramadan. 10(4), 503-507.
E. Burns (2017) Type 2 diabetes symptoms - drinking alcohol could reduce disease risk. (2017). http://www.express.co.uk/life-style/health/833802/type-2-diabetes-symptoms-drinking-alcohol-reduce-risk
J. Buse, B. Gumbincr, N. Mathais, D. Nelson, B. Jaja, R. Whitcomb (1998) For the Troglitazone study group: troglitazone use in insulintreated type 2 diabetic patients. 21(9), 1455-1461. https://doi.org/10.2337/diacare.21.9.1455
J. Buse (1999) Overview of current therapeutic actions in type 2 diabetes. Rationale for combining oral agents with insulin therapy. 22, 65-70.
M. Catalan, Z. Herreras, I. Pinyo, A. Sala-Vila, A. Amor, E. de Groot, t. Gilaber, E. Ros (2015) Prevalence by sex of preclinical carotid atherosclerosis in newly diagnosed type 2 diabetes. 25(8), 742-748. https://doi.org/10.1016/j.numecd.2015.04.009
J. Chang, Y. Li, Y. Huang, K. Lam, R. Hoo, W. Wong (2010) Adiponectin Prevents Diabetic Premature Senescence of Endothelial Progenitor Cells and Promotes Endothelial Repair by Suppressing the p38 MAP Kinase/p16INK4A Signaling Pathway. 59(11), 2949-2959. https://doi.org/10.2337/db10-0582
C. Chukwuma Sr (2014) Is diabetes a model for gene-environment interaction in premature senescence?. http://www.iiste.org/Journals/index.php/JBAH/article/viewFile/17380/17802
C. Chukwuma Sr (2017) Carbohydrate-lipid interactions in obesity and diabetes. http://asdpub.com/index.php/basr/article/view/361
Chukwuma Sr, C. (2017) Clinical, economic and healthcare constraints and challenges using insulin analogues in the treatment and control of diabetes in vulnerable populations. http://asdpub.com/index.php/ams/article/view/355
C. Chukwuma Sr (2017) Syndemics of chronic and acute diseases in vulnerable populations. http://asdpub.com/index.php/ams/article/view/360
M. de Kleijn, Y. van der Schouw, P. Wilson, D. Grobbee, P. Jacques (2002) Dietary Intake of Phytoestrogens Is Associated with a Favorable Metabolic Cardiovascular Risk Profile in Postmenopausal U.S. Women: The Framingham Study. 132(2), 276-282.
V. de Mello, J. Lindstrom, J. Eriksson, P. Illane-Parikka, S. Keinnanen-Kiukaanniemi, J. Pihlajamaki, J. Tuomilehto, M. Uusitupa (2015) Markers of cholesterol metabolism as biomarkers in predicting diabetes in the Finnish Diabetes Prevention Study. 25(7), 635-642. https://doi.org/10.1016/j.numecd.2015.03.012
K. Dungan, A. DeSantis (2017) Dipeptidyl peptidase-4 (DPP-4) inhibitors for the treatment of type 2 diabetes mellitus. https://doi.org/10.1002/cca.55
R. Godinho, C. Mega, E. Teixeira-de-Lamos, E. Carvalho, F. Teixeira, R. Fernandes, F. Reis (2015) The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?.
A. Golay, N. Guillet-Dauphine, A. Fendal, Juge C, J. Assal (1995) The insulin-sparing effect of metformin in insulin-treated diabetic patients. 011(1), S63-S67. https://doi.org/10.1002/dmr.5610110510
V. Higgins, J. Piercy, A. Roughley, G. Milligan, A. Leith, J. Sidall, M. Benford (2016) Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Volume 9, 371-380.
T. Kadowaki, T. Yamauchi, N. Kubota, K. Hara, K. Ueki, K. Tobe (2006) Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. 116(7), 1784-1792. https://doi.org/10.1172/jci29126
B. Kappel, N. Marx, M. Federici (2015) Oral hypoglycemic agents and the heart failure conundrum: Lessons from and for outcome trials. 25(8), 697-705. https://doi.org/10.1016/j.numecd.2015.06.006
S. Khan, R. Hull, K. Utzschneider (2007) Mechanisms linking obesity to insulin resistance and type 2 diabetes. 444, 840-846.
J. Lampe (2003) Isoflavonoid and Lignan Phytoestrogens as Dietary Biomarkers. 3, 9565-9645.
Sylvia Ley, Osama Hamdy, Viswanathan Mohan, Frank Hu (2014) Prevention and management of type 2 diabetes: dietary components and nutritional strategies. 383(9933). https://doi.org/10.1016/s0140-6736(14)60613-9
Y. Li, L. Li, L. Wang, Y. Guo, A. You, YL Xi, C. Wang (2014) Resting heart rate as a marker for identifying the risk of undiagnosed type 2 diabetes mellitus: a cross-sectional survey. 14(1), 1052. https://doi.org/10.1186/1471-2458-14-1052
X. Liu, Y. Li, L. Li, L. Zhang, Y. Ren, H. Zhou, L. Cui (2016) Prevalence, awareness, treatment, control of type 2 diabetes mellitus and risk factors in Chinese rural population: the Rural Diab study. 6(1), 31426. https://doi.org/10.1038/srep31426
C. Maadjhou, C. Nganou-Gnindjio, Azabji- N, Kuate M, M. L, A. Bimbai, Katte M, N. JC, Sobngw E (2017) The effect of optimizing glycemic control using insulin on the heart rate variability in type 2 diabetes mellitus patients. PAMJ - Conference Proceedings. 2(2), 20. https://doi.org/10.11604/pamj.cp.2017.2.20.50
P. Marques-Vidal, P. Vollenweider (2015) Alcohol consumption and incidence of type 2 diabetes. Results from the CoLaus study. 25(1), 75-84. https://doi.org/10.1016/j.numecd.2014.08.010
Christopher McIntosh, Hans-Ulrich Demuth, J. Pospisilik, Raymond Pederson (2005) Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents/ Regulatory Peptides. 128(2), 159-165. https://doi.org/10.1016/j.regpep.2004.06.001
MDedge (2004) Starting insulin in type 2 diabetes: Continue oral hypoglycemic agents?. 53(5), 393-399.
M. Monami, I. Iacomelli, E. Mannuci (2010) Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials. 20(4), 224-235. https://doi.org/10.1016/j.numecd.2009.03.015
S. Montilla, G. Marchesini, A. Sammarco, M. Trotta, P. Siviero, C. Tomino (2014) Drug utilization, safety, and effectiveness of exenatide, sitagliptin, and vildagliptin for type 2 diabetes in the real world: Data from the Italian AIFA Anti-diabetics Monitoring Registry. 24(12), 1346-1353. https://doi.org/10.1016/j.numecd.2014.07.014
NCD (2016) Risk Factor Collaboration (NCD-RisC. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. 387(10027), 1513-1530.
M. Nishimura, Y. Izumiya, A. Higuchi, R. Shibata, J. Qui, C. Kudo (2008) Adiponectin Prevents Cerebral Ischemic Injury Through Endothelial Nitric Oxide Synthase-Dependent Mechanisms. 117(2), 216-223. https://doi.org/10.1161/circulationaha.107.725044
Abdulfatai Olokoba, Olusegun Obateru, Lateefat Olokoba (2012) Type 2 Diabetes Mellitus: A Review of Current Trends. 27(4), 269-273. https://doi.org/10.5001/omj.2012.68
A. Pan, Chen Sun J, Li Ya X, Yu Z (2007) Effects of a flaxseed-derived lignin supplement in type 2 diabetic patients: a randomized, double-blind cross-over trial. 2(11), e1148. https://doi.org/10.1371/journal.pone.0001148
Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff, Christian Lerch (2008) Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. 2010(1), 6739. https://doi.org/10.1002/14651858.cd006739.pub2
M. Riddle (1996) combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine. 28(9), 430-433. https://doi.org/10.1055/s-2007-979832
I. Rowland, M. Faughnan, L. Hoey, K. Wahala, G. Williamson, A. Cassidy (2003) Bioavailability of phyto-oestrogens. S45-S58.
D. Russell-Jones, M-A Gall, M. Niemeyer, M. Diamant, S. Del Prato (2015) Insulin degludec results in lower rates of nocturnal hypoglycaemia and fasting plasma glucose vs. insulin glargine: A meta-analysis of seven clinical trials. 25(10), 898-905. https://doi.org/10.1016/j.numecd.2015.06.005
G. Sartore, R. Seraglia, S. Burlina, A. Bolu, R. Marin, E. Manzato, E. Raggazi, P. Traidi, A. Lapolla (2015) High-density lipoprotein oxidation in type 2 diabetic patients and young patients with premature myocardial infarction. 25(4), 418-425. https://doi.org/10.1016/j.numecd.2014.12.004
U. Schwab, M. Uusitupa (2015) Erratum to "Diet heart controversies - Quality of fat matters" [Nutr Metab Cardiovasc Dis 25 (2015) 617-622]. 25(7), 617-622.
Ouchi Shibata R, Ito N, Kihara M, Shiojima S, Pimental I, Kumada D.R, Sato M, K (2004) Adiponectin-mediated modulation of hypertrophic signals in the heart. 10(12), 1384-1389. https://doi.org/10.1038/nm1137
R. Shibata, K. Sato, D. Pimental, Y. Takemura, S. Kihara, K. Ohashi, T. Funahashi (2005) Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2-dependent mechanisms. 11(10), 1096-1103. https://doi.org/10.1038/nm1295
S. Singla, K. Kaur, G. Kaur, H. Kaur, J. Kaur, S. Jaswa (2009) Lipoprotein (a) in type 2 diabetes mellitus: Relation to LDL:HDL ratio and glycemic control. 29(2), 80. https://doi.org/10.4103/0973-3930.53125
I. Sluijs, E. Cadier, J. Beulens, D. Van Der A, A. Spijkerman, Y. van der Schouw (2015) Dietary intake of carotenoids and risk of type 2 diabetes. 25(4), 376-381. https://doi.org/10.1016/j.numecd.2014.12.008
S. Stoimeni, T. Karagiannis, A. Katsoula, E. Athanasiadou, K. Kazakos, E. Bekiari (2017) Once-weekly dipeptidyl peptidase-4 inhibitors for type 2 diabetes: a systematic review and meta-analysis. 18(9), 843-851. https://doi.org/10.1080/14656566.2017.1324848
Mohammad Talaei, A. Pan (2015) Role of phytoestrogens in prevention and management of type 2 diabetes. 6(2), 271. https://doi.org/10.4239/wjd.v6.i2.271
Belanger Thibault V, LeBlanc M, Babin E, Halpine L, Greene S, B, M. Mancuso (2016) Factors that could explain the increasing prevalence of type 2 diabetes among adults in a Canadian province: a critical review and analysis. 8(1), 71. https://doi.org/10.1186/s13098-016-0186-9
Pragya Tiwari (2015) Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update. 2015, 1-11. https://doi.org/10.1155/2015/340838
USFDA (2016) FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. https://www.fda.gov/Drugs/DrugSafety/ucm459579.htm
J. Utumatwishima, Baker N, Bingham R, Ricks B, Mabundo M, Galvan-Delacruz L, Onuzumike M, Sacks A, Chung D, S, A. Sumner (2017) High allostatic load score identifies African immigrants at increased risk for diabetes and cardiovascular disease: the Africans in America Study. 1(2), 3. https://doi.org/10.11604/pamj.cp.2017.2.3.42
Jean Utumatwishima, Rafeal Baker, Brianna Bingham, David Sacks, Anne Sumner (2017) HbA1C and fasting glucose perform poorly as screening tests for diabetes in African immigrants: the Africans in America study. 1(2). https://doi.org/10.11604/pamj.cp.2017.2.2.41
L. Valsta, A. Kilkkinen, W. Mazur, T. Numir, A. Lampi, M. Ovanskainen (2003) Phyto-oestrogen database of foods and average intake in Finland. S31-S38.
N. Vibhuti (2016) S. Low HDL cholesterol (hypoalphalipoproteinemia) and management. (2016). http://emedicine.medscape.com/article/127943-treatment
Estelle Well, Simeon Choukem, Mesmin Dehayem, Jean-Claude Katte, Jean Mbanya, Eugene Sobngwi (2017) Short term effects of liraglutide versus vildagliptin on insulin secretion and sensitivity in type 2 diabetes (Liravis study). 1(2), 16. https://doi.org/10.11604/pamj.cp.2017.2.16.46
WHO (2015) Global action plan for the prevention and control of noncommunicable diseases 2013- 2020, August 14, 2015, WHO, Geneva. 9789241506236.
S. Wu, I. Hopper, M. Skibo, H. Krum (2014) Dipeptidyl Peptidase‐4 Inhibitors and Cardiovascular Outcomes: Meta‐Analysis of Randomized Clinical Trials with 55,141 Participants. 32(4), 147-158. https://doi.org/10.1111/1755-5922.12075
X. Zhang, XO Sho, YB Xiang, G. Yang, H. Li, H. Cai, YT Gao, W. Zheng (2010) Resting heart rate and risk of type 2 diabetes in women. 39(3), 900-906.
Published
2017-11-20
Issue
Section
License
Copyright (c) 2017 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.